Madrigal Press Releases

Madrigal Pharmaceuticals

Skip to content

About Us
Our Approach
News Room
Investors

News Room

Headlines
Presentations
NASH Experts Webcasts
Media Contact

Headlines

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
October 4, 2021

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
August 5, 2021

Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
August 2, 2021

Press Release History

©2020 Madrigal Pharmaceuticals, Inc. All rights reserved.

- About Us
- Our Approach
- News Room
- Investors
- Contact Us
- Legal
- Privacy
- Cookies

Madrigal Pharmaceuticals
200 Barr Harbor Drive Suite 200 West Conshohocken, PA 19428

Madrigal Clinical Trials

Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)

Website Developed by Alan Leff Associates, Inc.